Pacira BioSciences, Inc. filed thirteen post-effective amendments to its Form S-8 registration statements on November 17, 2026, deregistering all previously registered but unsold shares of common stock following its merger with Viatris Inc.

Key Highlights

  • Merger completed November 17, 2026: Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., merged with and into Pacira BioSciences, with Pacira surviving as a wholly owned subsidiary of Viatris, according to the filing.
  • Thirteen registration statements terminated: The post-effective amendments cover Registration Nos. 333-175101 through 333-297971, spanning filings originally made between June 2011 and August 2026.
  • Multiple equity plans affected: The deregistered shares were associated with the Amended and Restated 2011 Stock Incentive Plan, the Amended and Restated 2014 Employee Stock Purchase Plan, and the Amended and Restated 2014 Inducement Plan, among others.
  • No shares remain registered: The filing states that "after giving effect to these Post-Effective Amendments, there will be no remaining Shares registered by the Company pursuant to the Registration Statements."
  • Merger Agreement dated October 8, 2026: The transaction was governed by an Agreement and Plan of Merger among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
  • Signed by President Michael Rainerman: The amendments were executed on behalf of Pacira BioSciences in Brisbane, California, on November 17, 2026.

Pacira BioSciences Closes Viatris Acquisition and Winds Down Employee Equity Programs

Pacira BioSciences, Inc., a Delaware corporation headquartered at 2000 Sierra Point Parkway, Suite 900, Brisbane, California, filed these post-effective amendments to terminate all offerings and sales of common stock, par value $0.001 per share, that had been registered under thirteen separate Form S-8 registration statements. The company disclosed that the action followed the closing of its merger with Viatris Inc. on November 17, 2026, pursuant to an Agreement and Plan of Merger dated October 8, 2026. Under that agreement, Peach Purchaser Sub Inc., a wholly owned Viatris subsidiary, merged with and into Pacira BioSciences, leaving Pacira as a wholly owned subsidiary of Viatris.

The registration statements being terminated covered share pools originally filed with the SEC across a span of more than fifteen years. These included 2,158,506 shares registered in June 2011 under the Pacira Pharmaceuticals, Inc. 2007 Stock Option/Stock Issuance Plan, 4,000,000 shares added in June 2016 under the Amended and Restated 2011 Stock Incentive Plan, and 800,000 shares registered as recently as August 4, 2026, under the Amended and Restated 2014 Employee Stock Purchase Plan. The company indicated it had undertaken in each of the original registration statements to remove unsold shares by post-effective amendment upon termination of the related offerings, and these amendments fulfill that commitment.

The filing was classified as a large accelerated filer at the time of submission. Counsel listed for the transaction included attorneys from Cravath, Swaine and Moore LLP in New York. The filing was signed by Michael Rainerman in his capacity as President of Pacira BioSciences, Inc. Following effectiveness of these amendments, Pacira BioSciences will have no shares registered under any of the thirteen enumerated registration statements.

What Was Disclosed

Pacira BioSciences filed post-effective amendments on November 17, 2026, to deregister all unsold shares under thirteen S-8 registration statements, following the completion of its acquisition by Viatris Inc. and the termination of all related equity plan offerings.